Hepatocellular Carcinoma Rupture after Introducing Lenvatinib: An Autopsy Case Report

Hepatocellular carcinoma (HCC) hemorrhaging/rupture is a rare adverse effect of lenvatinib, and only limited pathological examinations have been reported. This report presents the case of a 69-year-old man who suffered from cardiac arrest and died 7 days after starting lenvatinib treatment for HCC,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kohya, Risako, Sugiura, Ryo, Yamamoto, Yoshiya, Naruse, Hirohito, Hatanaka, Kazuteru, Kinoshita, Kenji, Abiko, Satoshi, Miyamoto, Shuichi, Suzuki, Kazuharu, Kushibiki, Hanae, Munakata, Satoru, Shimoyama, Norihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10125806/
https://www.ncbi.nlm.nih.gov/pubmed/36047124
http://dx.doi.org/10.2169/internalmedicine.0114-22
Descripción
Sumario:Hepatocellular carcinoma (HCC) hemorrhaging/rupture is a rare adverse effect of lenvatinib, and only limited pathological examinations have been reported. This report presents the case of a 69-year-old man who suffered from cardiac arrest and died 7 days after starting lenvatinib treatment for HCC, with an autopsy subsequently performed. Crack and coagulated blood were observed in the largest tumor. Pathologically, the hemorrhaging area was scattered in nearly all of the HCC lesions, regardless of tumor differentiation. This pathological feature is unusual in normal HCC. Thus, it is believed to have been the effect of lenvatinib.

Ejemplares similares